Bristol-Myers Squibb

  • Rigel and Bristol-Myers Squibb (BMS) have a research and development collaboration for TGF beta receptor kinase inhibitors for use in Immuno-Oncology related indications.

  • TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body.

  • The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors.

  • BMS obtained exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, those which may be approved to treat cancer.

  • BMS has identified a TGF beta-receptor kinase inhibitor molecule for IND-enabling toxicology studies, resulting an a $3 million milestone payment to Rigel.